Evidence map›Paper›PMID 19789647›Full record

Trial reportPloS one2009

Dexamethasone, cerebrospinal fluid matrix metalloproteinase concentrations and clinical outcomes in tuberculous meningitis.

Justin A Green, Chau T H Tran, Jeremy J Farrar, Mai T H Nguyen, Phu H Nguyen, Sinh X Dinh, Nghia D T Ho, Chuong V Ly, Hien T Tran, Jon S Friedland and 1 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 2 pooled it
5.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Adjunctive steroid therapy for managing pulmonary tuberculosis.The Cochrane database of systematic reviews · 2014
    Pooled it
  3. Towards host-directed therapy: The role of matrix metalloproteinases in the immunopathogenesis of tuberculosis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026
    Review
  4. Article
  5. Observational
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. MMPs and ADAMs in neurological infectious diseases and multiple sclerosis.Cellular and molecular life sciences : CMLS · 2019
    Review
  14. Review
  15. Article
  16. Review
  17. Adjunctive Corticosteroid Therapy in the Treatment of Coccidioidal Meningitis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017
    Article
  18. Observational
  19. Review
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Justin A GreenDepartment of Infectious Diseases and Immunity, Imperial College London, London, United Kingdom.
Chau T H Tran
Jeremy J Farrar
Mai T H Nguyen
Phu H Nguyen
Sinh X Dinh
Nghia D T Ho
Chuong V Ly
Hien T Tran
Jon S Friedland
Guy E Thwaites
Hospital for Tropical Diseases · VNImperial College London · GBOxford University Clinical Research Unit · VN

Funding

Medical Research Council G0500385Wellcome Trust
6 · The paper itself

Abstract

backgroundAdjunctive dexamethasone reduces mortality from tuberculous meningitis, but how it produces this effect is not known. Matrix metalloproteinases (MMPs) are important in the immunopathology of many inflammatory CNS diseases thus we hypothesized that that their secretion is important in TBM and might be influenced by dexamethasone. METHODOLOGY/PRINCIPAL

findingsThe kinetics of cerebrospinal fluid (CSF) MMP and tissue inhibitors of MMPs (TIMPs) concentrations were studied in a subset of HIV uninfected adults (n = 37) with TBM recruited to a randomized, placebo-controlled trial of adjuvant dexamethasone. Analysis followed a pre-defined plan. Dexamethasone significantly reduced CSF MMP-9 concentrations in early follow up samples (median 5 days (range 3-8) of treatment), but had no significant influence on other MMPs/TIMPs. Additionally CSF MMP-9 concentration was strongly correlated to concomitant CSF neutrophil count. CONCLUSIONS/SIGNIFICANCE: Dexamethasone decreased CSF MMP-9 concentrations early in treatment and this may represent one mechanism by which corticosteroids improve outcome in TBM. The strong correlation between CSF MMP-9 and neutrophil count suggests that polymorphonuclear leukocytes may play a central role in the early pathogenesis of TBM.

Indexed as

AdultCerebrospinal FluidChemotherapy, AdjuvantDexamethasoneFemaleGlucocorticoidsHumansKineticsMaleMatrix Metalloproteinase 9Matrix MetalloproteinasesMiddle AgedNeutrophilsPlacebosTreatment OutcomeTuberculosis, MeningealDexamethasoneGlucocorticoidsMatrix Metalloproteinase 9Matrix MetalloproteinasesPlacebos

Identifiers

PMID19789647
PMCPMC2748711
OpenAlexW2071175772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.